Details of the Drug-Related molecule(s) Expression Atlas

General Information of Drug (ID: DMSLQW2)

Drug Name
TRPH-222 Drug Info
Indication
Disease Entry ICD 11 Status REF
B-cell lymphoma 2A86 Phase 1 [1]
Non-hodgkin lymphoma 2B33.5 Phase 1 [1]
Cross-matching ID
TTD Drug ID
DMSLQW2

Molecule(s) Related to This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
B-cell receptor CD22 (CD22) TTM6QSK CD22_HUMAN Not Available [2]

The Expression Level of Molecule(s) between Disease Section and Healthy Individual Tissue

The Studied Disease B-cell lymphoma
ICD Disease Classification 2A86
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
B-cell receptor CD22 (CD22) DTT CD22 1.89E-11 -0.21 -0.58
Molecular Expression Atlas between Disease Section and Healthy Individual Tissue

References

1 ClinicalTrials.gov (NCT03682796) Study of TRPH-222 in Patients With Relapsed and/or Refractory B-Cell Lymphoma. U.S. National Institutes of Health.
2 Clinical pipeline report, company report or official report of Triphase Accelerator.